“In the early days, we knew where we were going,” adds Eric Brown, a professor of Biochemistry and Biomedical Sciences and one of the IIDR’s first members. “We set our compass for an ambitious journey, and we set a standard for ourselves, for our trainees, and for our staff.”
Decades later, Brown says that journey is looking more and more like a destination, though he notes those early ambitions for more still endure today. The small team that he and Wright helped establish has since grown into a full-fledged research enterprise with more than 50 dedicated infectious disease experts and hundreds of specialized trainees and staff, all working together across diverse areas of infectious disease research.
Over the past five years alone, this group has collectively made numerous landmark breakthroughs in infectious disease, including the discovery of an entirely novel class of antibiotics, along with new antifungals, adjuvants, and antimalarials; the development of an inhaled COVID-19 vaccine; successful applications of AI to drug discovery; the discovery of new antibiotic-producing gene clusters; and new insights into past pandemics, like the Black Death, drawn from ancient DNA.
Much of this work has been enabled by the IIDR’s core infrastructure, including the Centre for Microbial Chemical Biology, the David Braley Centre for Antibiotic Discovery, and McMaster’s Containment Level 3 laboratory. These state-of-the-art facilities give McMaster researchers open access to the equipment and expertise needed for high-impact science.
“We have a really full-service research ecosystem that allows researchers to get in from the basic level all the way through to translation,” says Lindsay Kalan, the IIDR’s associate director. “This core infrastructure is completely unique to an academic setting. It allows investigators to come in, learn skills, and access equipment that’s often only accessible at large pharmaceutical companies or in industry.”
The IIDR’s infrastructure is being increasingly leveraged for translating discoveries into tangible health solutions. In fact, in partnership with NexusHealth, a team of IIDR researchers has recently advanced its aforementioned inhaled vaccine platform to Phase 2 human trials.
“What I appreciate about McMaster has been the opportunity to step from bench to bedside,” says IIDR member Fiona Smaill, who is co-leading the ongoing clinical trials. “People talk about bench to bedside, but we actually do bench to bedside. This has allowed us to establish a generation of research scientists who can see that that their work has clinical impact.”
For IIDR member Jon Stokes, who blends computational and wet lab approaches to drug discovery, McMaster’s success in infectious disease research stems from the Institute’s right-sizedness.
“Institutes can get so big where you don’t know anybody and you feel siloed, even though that vast collection of people has every type of expertise you could hope for,” he says. “At the other end, you can have an institute that’s too small, where you do know everybody, but the diversity of expertise is insufficient to solve complex, multi-property problems like those in infectious disease. The IIDR is right in the Goldilocks zone.”
Talented people. A culture of crossing disciplines. A shared ambition. Critical infrastructure. Translational research. And a scale for impact. Every IIDR member seemingly has a different answer for why McMaster has landed among the world’s top institutions for infectious disease research — a testament, Wright says, to the many strengths of the Institute.
“You’re not going to find a place that’s better equipped, that has more collaborative individuals, or people who are more interested in moving the needle in infectious disease research anywhere in the world,” Wright says. “The IIDR is an absolute gem, and I couldn’t be more proud to be a member of it.”